Adjuvant Hepatic Arterial Chemotherapy Following Metastasectomy in Patients with Isolated Liver Metastases

Annals of Surgery

Volumn 237, Issue 6, 2003, Pages 782-789

  Onaitis, Mark ^a,b   Morse, Michael ^a   Hurwitz, Herbert ^a   Cotton, Peggy ^a   Tyler, Douglas ^a   Clavien, Pierre ^b   Clary, Bryan ^a   Blumgart, Leslie H ^b   McMasters, Kelly M ^b   Chapman, William C ^b   Daly, John M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Surgery ^*

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; BILE DUCT DISEASE; BILIARY TRACT DISEASE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DEMOGRAPHY; DISEASE COURSE; FEMALE; HEPATIC ARTERY; HUMAN; INFECTION; LIVER ABSCESS; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; STENT; SYSTEMIC DISEASE; WOUND INFECTION; ADJUVANT CHEMOTHERAPY; ARTICLE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; INFUSION PUMP; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; INFUSION PUMPS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85047692576     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SLA.0000071561.76384.19     Document Type: Conference Paper

References (25)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer Clin. 1999;49:8-31.
2. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. Cancer. 1969;23:198-202.
3. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976;2:285-288.
4. Fong Y, Fortner JG, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230:309-321.
5. Scheele J, Stangl R, Atendorf-Hofman A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
6. Minigawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487-499.
7. Ambiru S, Miyazaki M, Isono T, et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum. 1999; 42:632-639.
8. Jamison R, Donohue J, Nagorney D, et al. Hepatic resection for metastatic colorectal cancer results in cure for some. Arch Surg. 1997;132:505-511.
9. Gayowski T, Iwatsuki S, Madariaga J, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116:703-711.
10. Welch J, Donaldson G. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 1978;189:496-502.
11. Nordlinger B, Quilichini M-A, Parc M, et al. Hepatic resection for colorectal liver metastases. Ann Surg. 1987;205:256-263.
12. Benson III AB. Therapy for advanced colorectal cancer. Semin Oncol. 1998;25:2-11.
13. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999;17:3560-3568.
14. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343: 905-914.
15. Ackerman NB. The blood supply of experimental liver metastases. Surgery. 1974;75:589-596.
16. Allen-Mersh TG, Earlem S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255-1260.
17. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-693.
18. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with coloreactal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646-1654.
19. Martin JK, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg. 1990;125:1022-1027.
20. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma - a randomized trial. Ann Intern Med. 1987;107: 459-465.
21. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112-1118.
22. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039-2048.
23. Kemeny N, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an Intergroup study. J Clin Oncol. 2002;20:1499-1505.
24. Lorenz M, Muller H, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg. 1998;228:756-764.
25. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327-334.